TLC 388

Drug Profile

TLC 388

Alternative Names: Lipotecan; TLC-388; TLC388 HCl

Latest Information Update: 01 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiwan Liposome Company
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Hedgehog protein inhibitors; Hypoxia-inducible factor 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma; Rectal cancer
  • No development reported Solid tumours
  • Discontinued Renal cell carcinoma

Most Recent Events

  • 25 Jan 2017 Taiwan Liposome Company plans a phase I/II trial for Hepatocellular carcinoma in Taiwan and China (IV) (NCT03035006)
  • 15 Mar 2016 Biomarkers information updated
  • 18 Jan 2016 Phase-II clinical trials in Rectal cancer in Taiwan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top